Related Experiment Video
Updated: Aug 8, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
Published on: February 10, 2013
Role of cardiac factors in the initial hypotensive action by beta-adrenoreceptor blocking agents
Insights
The initial drop in blood pressure from beta-blockers like timolol maleate involves reduced cardiac output and increased oxygen use, suggesting tissue underperfusion contributes to their hypotensive effect.
Area of Science:
- Cardiovascular Pharmacology
- Hypertension Research
- Hemodynamics
Background:
- The delayed blood pressure decrease following beta-blockade is not well understood.
- Limited data exists on hemodynamic changes during the initial hypotensive action of beta-blockers.
Purpose of the Study:
- To investigate the early hemodynamic events associated with the hypotensive action of timolol maleate.
- To explore the relationship between initial hemodynamic changes and subsequent blood pressure reduction.
Main Methods:
- Hemodynamic measurements (mean arterial blood pressure, cardiac output, arteriovenous oxygen difference) were taken in 10 essential hypertension patients.
- Frequent measurements were conducted for the first 30 hours after the initial dose, with follow-ups at 3 and 6 weeks.
Main Results:
- A significant blood pressure decrease (13.5 +/- 8.2 mm Hg) was observed by 3 hours after the first dose.
- This was preceded by an initial decrease in cardiac output and an increase in arteriovenous oxygen difference, without immediate blood pressure fall.
- The magnitude of initial cardiac output decrease and arteriovenous oxygen difference increase correlated with later blood pressure reduction.
Conclusions:
- Early tissue underperfusion, indicated by decreased cardiac output and increased arteriovenous oxygen difference, may play a role in the initial hypotensive effect of beta-blockers.
- Hemodynamic patterns differ between early and late treatment phases, similar to other antihypertensive agents.
Abstract:
The blood pressure decrease after beta-blockade is delayed and there are little data on the hemodynamic events associated with the initial decrease in blood pressure. The present study measured the hemodynamics of the initial hypotensive action of timolol maleate, a nonselective beta-adrenoreceptor blocking agent, in 10 patients with essential hypertension. Frequent measurements were made for the first 30 hours of treatment, and follow-up measurements made at 3 and 6 weeks. Before treatment, mean arterial blood pressure, cardiac output, and arteriovenous oxygen difference were 115.9 +/- 9.1 mm Hg, 4.65 +/- 1.05 liter/min, and 55.0 +/- 9.6 ml/liter, respectively. At 3 hours after the first dose of timolol, blood pressure had fallen 13.5 +/- 8.2 mm Hg (p less than 0.05). This was preceded by an initial decrease in cardiac output, which was not associated with a simultaneous decrease in blood pressure, and by an increase of arteriovenous oxygen difference. The early, statistically significant, decrease in cardiac output was followed by a return to normal output, which coincided with the onset of blood pressure reduction. The magnitude of the initial decrease of cardiac output and of the initial increase in arteriovenous oxygen difference was significantly correlated to the later decrease in blood pressure (7 hours after first dose). These hemodynamic observations are consistent with the notion that early underperfusions of tissue play a role in the initial hypotensive action of beta-blockers. After 6 weeks, the blood pressure remained lower but the cardiac output was again decreased at that point. As with many antihypertensive agents, there was a difference between the early and late hemodynamic pattern.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Types of β-Blockers
Heart Failure Drugs: β-Blockers

